Neurodegenerative Disorder Therapeutics Market By Indication Type (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, and Other Indication Types), By Drug Type (N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, and Other Drug Types), By Distribution (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis, and Forecast till 2029

The market for treatments for neurodegenerative disorders is divided into five regions in the region: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The target market was led by the North American market in 2018 and is predicted to remain so for the duration of the projected period. The aging population in the United States has led to an increase in the prevalence of neurological illnesses. By 2030, 1.2 million Americans are predicted to have Parkinson's disease, according to research released by the Parkinson's Association in 2018. Between 2018 and 2026, this disease is expected to quadruple due to ongoing population expansion. The target market in this region is also being driven by favorable healthcare reimbursement policies and increasing research and development (R&D) spending. The Asian market Pacific is anticipated to experience a significant CAGR mostly due to an aging population.